Covista Inc., together with its subsidiaries, provides healthcare education in the United States, Barbados, St. Kitts, and St. Maarten. It operates in three segments: Chamberlain, Walden, and Medical and Veterinary. The company provides degree programs, including bachelor's, master's, and doctoral degrees; and online certificate programs for nursing, health professions, medical, and veterinary postsecondary education, counseling, business, information technology, psychology, public health, social work and human services, public administration and public policy, and criminal justice. It also operates Chamberlain University, Walden University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine. The company was formerly known as Adtalem Global Education Inc. and changed its name to Covista Inc. in February 2026. Covista Inc. was incorporated in 1987 and is headquartered in Chicago, Illinois.
Ticker
CVSA
Exchange
NYSE
Sector
Consumer Defensive
Industry
Education & Training Services
Market cap
$3.70B
52-week range
$86.97 - $142.13
Valuation
Share price
$110.32 (close of Nov 6, 2026)
P/E (TTM)
14.80x
Price to book
2.60x
Price to free cash flow
10.44x
Enterprise value
$4.23B
Book value per share
$42.35
Price performance
Period
Change
1 day
-2.34%
5 days
-11.27%
1 month
-13.39%
3 months
-11.22%
6 months
-4.33%
Year to date
+6.62%
1 year
+15.96%
3 years
+99.86%
5 years
+246.26%
10 years
+378.61%
All time
+8,951.90%
Short interest
As of
Oct 15, 2026
Short % of float
11.58%
Shares short
2.78M
Days to cover
9.85
Change since prior report
+9.33%
Source
FINRA consolidated short interest
Profitability and growth
Return on equity
17.40%
Return on invested capital
13.00%
Return on assets
8.35%
Return on capital employed
15.87%
Gross margin
57.34%
Net margin
12.87%
EBITDA margin
22.44%
Revenue growth
9.27%
Net income growth
6.12%
Free cash flow growth
36.57%
Cash flow and balance sheet
Free cash flow yield (TTM)
9.58%
Current ratio
0.81x
Net debt to EBITDA
1.11x
Latest reported year
Period end
Jun 30, 2026
Fiscal year
2026
Revenue
$1.95B
Cost of revenue
$833.66M
Gross profit
$1.12B
EBITDA
$438.45M
Net income
$251.57M
Earnings per share
$7.18
Interest expense
$45.44M
Shares outstanding
35.05M
Income statement by year
Period end
Revenue
Gross profit
Net income
EPS
2026-06-30
$1.95B
$1.12B
$251.57M
$7.18
2025-06-30
$1.79B
$1.02B
$237.06M
$6.39
2024-06-30
$1.58B
$886.10M
$136.78M
$3.47
2023-06-30
$1.45B
$802.34M
$93.36M
$2.08
2022-06-30
$1.38B
$722.07M
$310.99M
$6.43
2021-06-30
$899.25M
$441.34M
$70.03M
$1.36
2020-06-30
$866.43M
$409.26M
-$85.33M
-$1.59
2019-06-30
$1.01B
$542.06M
$95.17M
$1.63
2018-06-30
$960.28M
$498.72M
$33.77M
$0.55
2017-06-30
$1.21B
$569.66M
$122.28M
$1.93
Margins and returns by year
Period end
Gross margin
Net margin
Return on equity
Return on capital
2026-06-30
57.34%
12.87%
17.40%
13.00%
2025-06-30
56.86%
13.26%
16.54%
12.49%
2024-06-30
55.92%
8.63%
9.99%
8.61%
2023-06-30
55.30%
6.43%
6.41%
6.71%
2022-06-30
52.25%
22.51%
20.85%
3.00%
2021-06-30
49.08%
7.79%
5.41%
3.79%
2020-06-30
47.24%
-9.85%
-6.52%
6.03%
2019-06-30
53.47%
9.39%
6.84%
6.86%
2018-06-30
51.94%
3.52%
2.22%
6.74%*
2017-06-30
47.16%
10.12%
7.33%
7.29%*
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.